Coverage Initiated on Developer of Neurodegenerative Disease Therapeutics
Source: Streetwise Reports  (7/1/19)
An H.C. Wainwright & Co. report presented the investment bank's reasons for its bullish view on this California-based biotech. More >

Biopharma Buys 'Insurance Policy Ahead of First Commercial Launch'
Source: Streetwise Reports  (7/1/19)
The terms of the financial transaction and the potential reasons for it are discussed in a BTIG report. More >

Biotech's Data Well Received at Neurodegenerative Diseases Symposium
Source: Streetwise Reports  (6/28/19)
The company shared findings from its lead clinical program, in Alzheimer's disease. More >

Biopharma Responds to FDA Inquiry Concerning Non-Opioid Pain Reliever
Source: Streetwise Reports  (6/28/19)
The firm believes adequate therapeutic safety and efficacy data exist to support regulatory approval. More >

Dova Pharmaceuticals Shares Increase 35% Overnight with FDA Approval
Source: Streetwise Reports  (6/27/19)
The pharmaceutical stock enjoyed a large boost, thanks largely to FDA approval of its supplemental new drug application for DOPTELET for treatment of chronic immune thrombocytopenia. More >

Strategic Partnership Highlights Global Ambitions for NASH Therapy
Source: Streetwise Reports  (6/26/19)
The deal terms and the partner's attractive attributes are discussed in an H.C. Wainwright & Co. report. More >

Coverage Initiated on 'Solid Platform Company' with Sanofi Partnership
Source: Streetwise Reports  (6/26/19)
The reasons why this biopharma makes a compelling investment are outlined in a ROTH Capital Partners report. More >

Biotech in Neuro Diseases Adds Parkinson's Expert to Scientific Advisory Board
Source: Streetwise Reports  (6/22/19)
The expert brings to the board a deep knowledge of neurodegeneration. More >

Biotech Reports 'Eye-Catching, Topline Results' from RSV Vaccine Study
Source: Streetwise Reports  (6/19/19)
The data and how the asset stacks up to others were covered in a ROTH Capital Partners report. More >

Precision Medicine Firm Announces 'Positive' Data in Lymphoma Study
Source: Streetwise Reports  (6/19/19)
The highlights of the results were presented in an H.C. Wainwright & Co. report. More >

Biopharma Advances Dose Escalation Trial in Alcoholic Hepatitis
Source: Streetwise Reports  (6/19/19)
The company received approval to proceed with the next and final dose level. More >

Interim Results Put Biopharma with Tenbagger Potential 'Back on the Map'
Source: Streetwise Reports  (6/11/19)
A key upcoming catalyst and the impact of recent positive trial results are addressed in a ROTH Capital Partners report. More >

Biotech to Present Alzheimer's Disease Therapeutic at Keystone Symposium
Source: Streetwise Reports  (6/8/19)
The focus will be the Canadian company's lead monoclonal antibody candidate. More >

Biopharma Receives FDA Fast Track Designation for Cancer Therapeutic
Source: Streetwise Reports  (6/5/19)
An explanation of the categorization and its implications are provided in a Paradigm Capital report. More >

Coverage Initiated on Biotech Whose Therapies 'Can Compete with CAR-Ts'
Source: Streetwise Reports  (6/5/19)
The reasons for the Buy rating on the U.K. firm are delineated in a ROTH Capital Partners report. More >

Biopharma's LDL Cholesterol-Lowering Drug Emerges as 'Lead Stallion in Safety'
Source: Streetwise Reports  (5/28/19)
The interim study results for an in-progress trial evaluating this asset are discussed in a ROTH Capital Partners report. More >

Biotech Identifies Antibodies for Toxic Tau in Alzheimer's Disease
Source: Streetwise Reports  (5/28/19)
The Canadian company's approach to this indication is now twofold. More >

California-Based Biopharma Signs Licensing Deal for Acquired Asset
Source: Streetwise Reports  (5/25/19)
The transaction details and the drug platform's potential are addressed in an H.C. Wainwright & Co. report. More >

Oncology Vaccine Developer's Lead Programs 'On Track or Better'
Source: Streetwise Reports  (5/22/19)
The biopharma's two assets are discussed and Q1/19 financial results are provided in a BTIG research report. More >

Immuno-oncology Firm to Co-Develop Companion Diagnostic for Cervical Dysplasia
Source: Streetwise Reports  (5/22/19)
The partnership news and upcoming data readouts are reviewed in an H.C. Wainwright & Co. report. More >

U.S. Biopharma's 'Biggest Stock Moving Event' Imminent
Source: Streetwise Reports  (5/22/19)
With study results from this company due out shortly, an analysis of the possible outcomes was provided in a ROTH Capital Partners report. More >

Cancer Fighter Sesen Bio Leaps 13% on FDA Decision
Source: Streetwise Reports  (5/21/19)
Shares of this biotech stock were up significantly at the close of trading on Tuesday, May 21, attributed to the announcement of some good news from the FDA. More >

Harrow Comes Out of Allergan Lawsuit Unscathed
Source: Daniel Carlson for Streetwise Reports  (5/17/19)
Sector expert Daniel Carlson offers his take on the recent jury decision, calling it "very positive." More >

Why Did ImmunoGen Plummet 32%?
Source: Streetwise Reports  (5/16/19)
This biotechnology company, which focuses on the treatment of cancer, received some feedback from the FDA that upset investors on Wednesday. More >

FDA Approval of Antibiotic for Bacterial Pneumonia Expected in Late Summer
Source: Streetwise Reports  (5/15/19)
An update on this biopharma's two lead drug candidate programs was provided in an H.C. Wainwright report. More >